Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-3C01 with PD-(L)1 antibody in advanced solid tumors (Phase I/II)
ChiCTR2600126590Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Jun 2026
- Countries
- 1
01
Overview
Phase 2, open-label trial of N-3C01 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), melanoma and 5 more (12 arms), sponsored by Shanghai East Hospital. Primary endpoints: Phase I Dose Escalation Study: Safety, Phase I Dose Escalation Study: Tolerability and 5 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
N-3C01
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)melanomacolorectal cancer (CRC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2600126590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126590.